EUVIMEDEUVIMED entdecken
Leitlinie

Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections--Duration of Antibiotics for Complicated UTI

Barbara W Trautner iD, Nicolás W Cortés-Penfield, Kalpana Gupta, Elizabeth B Hirsch, Molly Horstman, Gregory J Moran, Richard Colgan, John C O'Horo, Muhammad S Ashraf, Shannon Connolly, Dimitri Drekonja, Larissa Grigoryan iD und 6 weitere

Clinical Infectious Diseases · 24.08.2026 · 82 (Supplement_3) · i79-i88

DOI: 10.1093/cid/ciaf462 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 20.12.2025. Verfasst von Barbara W Trautner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Urinary Tract Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

These recommendations provide guidance on the optimal duration of antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia.

Methods

The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of shorter (5–7 days) vs prolonged (10–14 days) duration of antibiotics, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

Results

The guidelines panel suggests that patients with cUTI who are improving on effective therapy can be treated with shorter duration of antimicrobials (either 5–7 days of a fluoroquinolone or 7 days of a non-fluoroquinolone) rather than longer courses of antibiotics, regardless of the presence of associated Gram-negative bacteremia. An effective antimicrobial agent achieves therapeutic levels in the urine and relevant tissue and is active against the causative pathogen. However, men with febrile UTI in whom acute bacterial prostatitis is suspected may benefit from a longer treatment duration (10–14 days), and a short courses of oral beta lactams may require higher doses for efficacy.

Conclusions

Shorter durations of antibiotics for cUTI provide similar efficacy as longer courses, except in men with febrile UTI in whom acute bacterial prostatitis is suspected. This recommendation places a high value on antibiotic stewardship considerations as well as reducing the burden of antimicrobial administration from a healthcare perspective and reducing the burden of taking antibiotics from a patient perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsAnti-Bacterial AgentsHumansBacteremiaMaleFluoroquinolones

Substanzen

Anti-Bacterial AgentsFluoroquinolones

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, USA.
  • Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
  • Section of Infectious Diseases, Boston VA Health Care System, Boston University School of Medicine, Boston, MA, USA.
  • Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, USA.
  • Department of Medicine, Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA.
  • Clinical Emergency Medicine, David Geffen School of Medicine at UCLA, Olive View-UCLA Medical Center, Los Angeles, CA, USA.

ORCID-Profile: Barbara W Trautner, Larissa Grigoryan, Anthony Schaeffer

Zitieren

APA

Trautner, B. W., Cortés-Penfield, N. W., Gupta, K., Hirsch, E. B., Horstman, M., Moran, G. J., Colgan, R., O'Horo, J. C., Ashraf, M. S., Connolly, S., Drekonja, D., Grigoryan, L., Huttner, A., Lazenby, G. B., Nicolle, L., Schaeffer, A., Yawetz, S., & Lavergne, V. (2026). Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections--Duration of Antibiotics for Complicated UTI. Clinical Infectious Diseases, 82(Supplement_3), i79-i88. https://doi.org/10.1093/cid/ciaf462

Vancouver

Trautner BW, Cortés-Penfield NW, Gupta K, Hirsch EB, Horstman M, Moran GJ, et al. Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections--Duration of Antibiotics for Complicated UTI. Clinical Infectious Diseases. 2026;82(Supplement_3):i79-i88. doi:10.1093/cid/ciaf462

BibTeX
@article{Trautner2026,
  author = {Trautner, Barbara W and Cortés-Penfield, Nicolás W and Gupta, Kalpana and Hirsch, Elizabeth B and Horstman, Molly and Moran, Gregory J and Colgan, Richard and O'Horo, John C and Ashraf, Muhammad S and Connolly, Shannon and Drekonja, Dimitri and Grigoryan, Larissa and Huttner, Angela and Lazenby, Gweneth B and Nicolle, Lindsay and Schaeffer, Anthony and Yawetz, Sigal and Lavergne, Valéry},
  title = {Clinical Practice Guidelines by Infectious Diseases Society of America (IDSA): 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections--Duration of Antibiotics for Complicated UTI},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {Supplement_3},
  pages = {i79--i88},
  doi = {10.1093/cid/ciaf462}
}
Kostenlos starten →